Late Breaking Data from the Society for Immunotherapy of Cancer 2016
Combinatorial CD8+ and PDL1+ Cell Densities Correlate with Response and Improved Survival in NSCLC Patients Treated with Durvalumab
Sonja Althammer1, Keith Steele2, Marlon Rebelatto2, Tze Heng Tan1, Tobias Wiestler1, Günter Schmidt1, Brandon W. Higgs2, Xia Li2, Li Shi2, Xiaoping Jin2, Koustubh Ranade2
1. Definiens, Munich, Germany
2. MedImmune, Gaithersburg, MD USA
Date: December 6, 2016 (60 minutes)
Immunotherapies have improved patient responses and survival, though not all patients benefit. Effective biomarkers may help improve outcomes. Durvalumab is a human IgG1 monoclonal antibody that inhibits programmed death ligand-1 (PD-L1) binding to programmed death-1 and B7.1/CD80, restoring antitumor immunity. PD-L1 expression on tumor or tumor-infiltrating immune cells measured manually with different immunohistochemistry (IHC) assays can enrich for patients responding to anti-PD1/PD-L1 agents. Tumor-infiltrating cytotoxic CD8+ T cells may also have potential predictive utility for therapeutic response. We explored automated image analysis and pattern recognition of tumor biopsies to determine whether CD8+ and PD-L1+ cells densities could better identify patients most likely to respond to durvalumab than PD-L1 IHC alone.
In this webinar, Dr Althammer will demonstrate:
- How Tissue Phenomics® can support you to quantify different cell populations based on multiple biomarker expression profiles (CD8(+) and PD-L1(+)) and to further investigate correlations of the density of those populations to the clinical data
- How Tissue Phenomics® has been used to detect the improved predictive value for Durvalumab treatment by combining CD8 and PD-L1 evaluation compared to PD-L1 alone
The presentation represents the team effort of groups at DEFINIENS and MedImmune and was recently presented at the SITC conference.
Patients with high pretreatment CD8+ and PDL1+ densities (prevalence=36%) had better ORR, OS, and PFS compared to those with low CD8+ and PDL1+ densities, as well as high PDL1 expression alone.
Automated image analysis of CD8+ and PDL1+ cell densities in baseline tumor biopsies may identify patients with improved outcomes to durvalumab.
|ABOUT OUR SPEAKER|
Sonja Althammer, Bioinformatics Team Lead, Definiens
Sonja Althammer graduated in 2008 with a master degree in Bioinformatics from TU/LMU (Ludwig-Maximilians University) in Munich, Germany. Sonja went on to receive her PhD at the Universitat Pompeu Fabra (Barcelona, Spain) in 2012. Two years ago, she began her tenure at DEFINIENS as a research scientist where she has most recently joined the Professional Services Department to lead the Bioinformatics team.
|THIS PROGRAM IS INTENDED FOR|
This webinar will be ideal for Medical, Pharmaceutical, Biotech and Diagnostics executives, for directors and vice presidents of therapeutic areas and Chief Scientific, Medical and Executive Officers. It will also be informative for lab and study directors, and medical directors.
|OUR XTALKS PARTNER FOR THIS EVENT|
We improve patient lives by unlocking the tissue phenome.
In oncology, therapeutic strategies have shifted from a direct assault on cancer cells to recruiting the immune system for that purpose. Our mission is to accelerate breakthroughs for this approach by helping scientists leverage Tissue Phenomics to deepen understanding of disease biology and immune system mechanisms, to bring multi-omics data into a cancer-relevant context, and to facilitate the translation of new insights into novel therapies and treatment strategies. Our vision is to create unique patient profiles for an individualized standard of care, where patients experience fewer side effects and live longer.
Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.